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Integration of B-cell receptor-induced ERK1/2 
phosphorylation and mutations of SF3B1 gene
refines prognosis in treatment-naïve chronic 
lymphocytic leukemia
Signaling events downstream of the B-cell receptor
(BCR) are key determinants of the clinical behavior of
chronic lymphocytic leukemia (CLL).1,2 Extracellular signal-
regulated kinase 1/2 (ERK1/2) is a major pathway down-
stream of BCR stimulation.3,4 In a recent study, applying a
single cell network profiling (SCNP) assay5 to independent
sets of CLL samples, we characterized functional elements
of the BCR signaling network associated with clinical out-
comes in CLL and validated BCR-induced ERK1/2 phos-
phorylation as a significant, independent predictor of
faster clinical progression in CLL.6 Novel recurrent mutat-
ed genes have recently been associated with progressive or
high-risk disease and a dismal outcome in CLL.7,8 Gene
alterations occur during cancerous transformation and
evolution of the malignant clone, most likely favored by
signals from the BCR and microenvironment. Despite the
established driving role of BCR signaling and gene muta-
tions in CLL, little is known about the association between
functional BCR responses and specific genetic alterations.
Investigating the physiology of BCR signaling in the genet-
ic context would add useful information to improve prog-
nostic classification of CLL patients and gain deeper
insights into pathobiological mechanisms. Herein, we
investigated the impact of integrated BCR-induced ERK1/2
phosphorylation and recurrent gene mutations on progno-
sis of untreated CLL. We found that integrated dynamic
ERK1/2 phosphorylation and SF3B1 mutations are associ-
ated with the risk of disease progression and enable iden-
tification of a novel intermediate-risk group of patients. 
ERK1/2 phosphorylation (pERK1/2) was measured by
SCNP5,6 in 152 treatment-naïve CLL cell samples (Online
Supplementary Table S1), in basal condition and following
BCR stimulation with anti-IgM (Figure 1A,B). In the basal
condition, we detected no differences in pERK1/2
between subgroups of patients defined by IGHV muta-
tional status (UM: unmutated; M: mutated), CD38 expres-
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Figure 1. ERK1/2 phosphorylation in B cells from CLL patients. (A) Representative flow cytometry histograms of pERK1/2 in the basal condition or following
BCR modulation with anti-IgM in CD5+/CD19+ cells from CLL patients, compared with autofluorescence signals. (B) pERK1/2 in CLL patients, in the basal con-
dition and following anti-IgM modulation (n=152). Data are expressed as equivalent number of reference fluorophores (ERF). The results for basal and anti-IgM-
modulated CLL cells were compared by the two-sample Wilcoxon signed rank sum test. The lines indicate the medians. The Y-axis is expanded on low values.
(C-D) SCNP signals of pERK1/2 in the basal condition (C) and in response to anti-IgM stimulation (D) was associated with IGHV status (n=134), CD38 expression
(n=152), and cytogenetic mutations (n=141). Different sample sizes depend on availability of biological parameters. Data are expressed as equivalent number
of reference fluorophores (ERF) (C) and Uu (D) and represented as Tukey boxes and whiskers. The Mann-Whitney test and Kruskal-Wallis test were used for com-




sion and cytogenetic alterations (Figure 1C). In contrast,
pERK1/2 in response to BCR stimulation (anti-
IgM→pERK1/2) was higher in UM-CLL than in M-CLL
and higher in CD38-positive cases than in CD38-negative
cases (Figure 1D). Moreover, higher anti-IgM→pERK1/2
was associated with treatment requirement during follow-
up (Online Supplementary Table S2).
Mutations of NOTCH1, SF3B1, TP53, BIRC3, and
MYD88 genes were examined in CLL samples for which
DNA was available (146/152) by polymerase chain reac-
tion amplification and Sanger sequencing (details in Online
Supplementary Data). Due to the low number of BIRC3
(n=2/146) and MYD88 (n=2/146) mutations, these genes
were excluded from analysis.
NOTCH1 mutations were detected in 17/146 (12%)
samples. Of these 17 patients, 15 (88%) carried missense
mutations whereas 2/17 (12%) had non-sense events:
these latter were excluded from the analysis. NOTCH1
mutations were associated with higher CD38 expression
and showed a trend toward association with trisomy 12
(Figure 2A; Online Supplementary Table S3). No associations
were found between NOTCH1 mutations and anti-
IgM→pERK1/2 (Figure 2A; Online Supplementary Table S3). 
SF3B1 genetic lesions were detected in 19/146 (13%)
patients. These mutations were associated with 
UM-IGHV status (Figure 2A; Online Supplementary Table
S3) and more frequently detected in advanced (Binet stage
B-C) stage disease and in patients requiring treatment dur-
ing follow-up (Online Supplementary Table S2). Of note,
cases harboring SF3B1 mutations also exhibited a higher
anti-IgM→pERK1/2 (Figure 2A-B; Online Supplementary
Table S3). Given the strong association between anti-
IgM→pERK1/2 and UM-IGHV status (Figures 1D and 2A),
we sought to assess the influence of IGHV status on the
association between anti-IgM→pERK1/2 and SF3B1
mutations. Superimposition of IGHV status revealed that
in M-CLL SF3B1 mutations did not identify CLL sub-
groups with different anti-IgM→pERK1/2 (Figure 2B).
Therefore, in M-CLL SF3B1 mutations apparently did not
have a significant impact on anti-IgM→pERK1/2. In UM-
CLL, SF3B1-mutated cases exhibited a higher anti-
IgM→pERK1/2 than wild-type (wt) SF3B1 cases (Figure
2B). The more frequent association of UM-IGHV with
ERK1/2 responsiveness to BCR is, therefore, mainly
explained by UM-CLL samples that harbor SF3B1 muta-
tions. 
TP53 gene mutations were detected in 11/146 (8%) cell
samples, with one patient harboring two mutations. As
expected, TP53 lesions were enriched in patients with
del(17p) (Figure 2A; Online Supplementary Table S3). While
cases with TP53 lesions exhibited a trend toward associa-
tion with high anti-IgM→pERK1/2, cases with p53 dys-
function [TP53 lesions and/or del(17p)] showed no associ-
ation with high anti-IgM→pERK1/2 (Figure 2A; Online
Supplementary Table S3). 
Concurrent mutations were detected in only two cases
(coexisting NOTCH1 and TP53 mutations) and their asso-
ciation with pERK1/2 was not, therefore, investigated.
To assess the impact of pERK1/2 integrated with gene
mutations on disease progression, measured as time to
first treatment (TTFT), we examined time-to-event model-
ing utilizing ERK1/2 SCNP data, recurrent gene mutations,
IGHV status, CD38 expression, and cytogenetic alter-
ations – alone and in combination – in the whole set of
patients for whom all studied biological and TTFT data
were available (n=125/152). Univariate time-to-event
analysis identified higher anti-IgM→pERK1/2 (Figure 3A),
mutated SF3B1 (Figure 3B), UM-IGHV (P<0.0001), and
CD38-positivity (P=0.001) as significant, independent pre-
dictors of shorter TTFT. While high anti-IgM→pERK1/2
was not associated with shorter TTFT in the comprehen-
sive multivariate analysis, in a bivariate time-to-event
analysis high anti-IgM→pERK1/2 and SF3B1 mutation
were found to be independent, significant parameters of
prognosis (Online Supplementary Table S4A). Remarkably,
integrating anti-IgM→pERK1/2 data and SF3B1 mutation,
three independent prognostic categories were identified: a
low-risk group (n=42; patients requiring treatment=26%;
median TTFT=40 months) comprised patients with low
anti-IgM→pERK1/2 and wt SF3B1; an intermediate-risk
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Figure 2. Association of ERK1/2 phosphorylation in response to BCR stimulation with gene mutations.  (A) ERK1/2 phosphorylation in response to anti-IgM
stimulation (anti-IgM→pERK1/2) (n=152), expressed by the Uu metric, was associated with IGHV status, CD38 expression, NOTCH1, SF3B1 and TP53 muta-
tions, and cytogenetic mutations. Rows correspond to parameters and columns represent individual patients. Data are colored in: green = high IgM→pERK1/2,
red = positive for standard prognostic parameters, blue = presence of gene mutation, orange = positive for p53 dysfunction (TP53 mutation and/or del(17p)),
gray = negative, white = no available data. (B) anti-IgM→pERK1/2, expressed as Uu values, was associated with SF3B1 mutation in the entire set of patients
(left panel; n=146) and in the UM-CLL subset (right panel). Lines represent the mean values. Comparisons were performed using the Mann-Whitney test (left
panel) and Kruskal-Wallis test (right panel).
A
B
group (n=66; patients requiring treatment=48%; median
TTFT=34 months) included patients with low anti-
IgM→pERK1/2 and mutated SF3B1 or high anti-
IgM→pERK1/2 and wt SF3B1; and a high-risk group
(n=17; patients requiring treatment=82%, median TTFT=3
months) comprised patients with high anti-IgM→pERK1/2
and mutated SF3B1 (Figure 3C). 
A subset of Binet stage A patients for whom all biologi-
cal and TTFT data were available (n=90/112) was then
analyzed. Univariate time-to-event analysis identified
increased anti-IgM→pERK1/2 (Figure 3D), mutated SF3B1
(Figure 3E), mutated TP53 (P=0.001), UM-IGHV
(P<0.0001), and CD38-positivity (P=0.0006) as significant,
independent predictors of shorter TTFT. The bivariate
time-to-event analysis identified high anti-IgM→pERK1/2
and SF3B1 mutation as independent significant variables
in terms of TTFT (Supplementary Table S4B). Integrating
anti-IgM→pERK1/2 and SF3B1 mutation, we could strati-
fy early-stage patients into three independent prognostic
categories: a low-risk group (n=33; patients requiring treat-
ment=18%, median TTFT=47 months) comprised patients
with low anti-IgM→pERK1/2 and wt SF3B1; an interme-
diate-risk group (n=49; patients requiring treatment=37%,
median TTFT=42 months) included patients with low
anti-IgM→pERK1/2 and mutated SF3B1 or high anti-
IgM→p-ERK1/2 and wt SF3B1; and a high-risk group
(n=8; patients requiring treatment =75%, median
TTFT=16 months) comprised patients with high anti-
IgM→pERK1/2 and mutated SF3B1 (Figure 3F).
In this study, we measured ERK1/2 response to BCR in
association with NOTCH1, SF3B1, TP53 mutations with
the aim of integrating, for the first time, dynamic proper-
ties of BCR activation and driver-gene mutations in a prog-
nostic model for treatment-naïve CLL. Our data reveal that
integrating dynamic ERK1/2 phosphorylation and SF3B1
mutational status improves the prognostic potential of
pERK1/2 and SF3B1 alone and identifies three groups of
patients with distinct risks of disease progression.
The finding that high anti-IgM→pERK1/2 identifies a
subgroup of CLL treatment-naïve patients with a more
aggressive disease and a faster clinical progression con-
firms our previous data obtained from patients with early-
stage disease6 and extend them to patients with advanced-
stage disease. Overall, these data identify ERK1/2 as a rel-
evant node on the route of BCR signaling, which is able to
capture the behavior of other components of the pathway.
In line with this, ERK1/2 functions as a survival pathway9
and is required for cell cycle progression in CLL.10Of note,
a recent study showed that novel CLL driver mutations
affect the ERK pathway, with 8.7% of patients carrying at
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Figure 3. Kaplan-Meier curves of time to first treatment (TTFT). Kaplan-Meier curves of TTFT for the entire patient set for which biological parameters and clinical
data were available (n=125/152, A-C) or for the Binet stage A patients for whom biological parameters and clinical data were available (n=90/112, D-F). Curves
were defined by pERK1/2 response to BCR (anti-IgM→pERK1/2), using the pre-specified 0.66 Uu cut-off (A,D), the presence of SF3B1 mutations (B,E), or the
integrated anti-IgM→ pERK1/2 data (cut-off=0.66) and SF3B1 mutations (C,F). 
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least one gene mutation in this pathway.11 Interestingly,
the response of ERK1/2 to BCR, rather than its basal phos-
phorylation state, is associated with standard prognostic
parameters (UM-IGHV and CD38 positivity, but not cyto-
genetic alterations) and disease progression, supporting
the determinant role of dynamic properties of BCR signal-
ing in CLL. These data are in agreement with a recent
study by D’Avola et al. showing that BCR responsiveness,
measured as percentage of intracellular Ca2+ mobilization,
is associated with UM-IGHV and CLL aggressiveness.2 In
contrast with our results, that study showed an association
between BCR responsiveness and trisomy 12 and del(17p).
These discrepancies might be due to differences in sets of
patients and measurements of BCR response.
To measure ERK1/2 signaling in this study, we used
SCNP, a phospho-specific assay based on flow cytometry,
which provided ERK1/2 readout metrics for developing a
mathematical model for the prediction of CLL
progression.5,6 Overall, this study confirms that SCNP can
capture biologically and clinically relevant information on
pathological cells.
As expected, mutations of NOTCH1, SF3B1 and TP53
genes were more frequently detected in patients with
unfavorable clinico-biological features.8,12,13 This was specif-
ically pronounced for SF3B1, whose mutations were
enriched in UM-CLL, advanced disease, and patients
requiring treatment during follow-up. SF3B1 mutations
were also associated with a higher response of ERK1/2 to
BCR, specifically in UM-CLL. In contrast, D’Avola et al.
revealed differential BCR responses between wt and
mutated SF3B1 in M-CLL but not in UM-CLL.2 Besides dif-
ferences in the BCR-response measurements, this discrep-
ancy may be due to the low number of cases with SF3B1
mutations (7 in the study by D’Avola et al. and 3 in ours).
Further studies with larger series of patients are required to
address this issue. 
Only SF3B1 mutations integrated with anti-
IgM→pERK1/2 can refine prognosis in CLL, which might
suggest a direct effect of SF3B1 mutations on BCR signal-
ing. SF3B1 is a core component of the RNA splicing
machinery14 and, among other effects, SF3B1 mutations
might induce alternative splicing of the BCR component
CD79b. A change in the balance between the entire
CD79b transcript and the alternative spliced form could
account for altered BCR expression and function in CLL.15
In conclusion, this study shows that integrated ERK1/2
response to BCR stimulation and SF3B1 gene mutations
refine prognosis in CLL and may form the basis for future
investigations aimed at validating an integrated prognostic
model including dynamic properties of BCR and SF3B1
mutation in CLL. 
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